Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

Edgewise Therapeutics received favorable FDA feedback and submitted the Phase 3 STRATUS-HCM protocol for EDG-7500, with the trial on track to start in Q4 2026. The global study plans to enroll approximately 600 adults—about 200 with obstructive and 400 with nonobstructive HCM—and will use change in peak VO₂ at Week 24 as its primary endpoint. Investigator-assessed tolerability, rather than echocardiograms, will guide escalation from 50 mg to 100 mg and then 150 mg daily; the EMA and Japan's PMDA gave generally consistent feedback on the approach.

Analysis

The regulatory signal reduces one execution risk—whether a scalable, echo-independent titration plan is acceptable—but it does not validate EDG-7500’s efficacy or safety. The economic value hinges on whether patients can reach and sustain effective doses without echo-guided decisions; investigator-led escalation could lower site burden and broaden eventual access, yet increase dose variability and make tolerability, adherence and exposure-response data pivotal. That trade-off is particularly important if the nonobstructive cohort is to support a differentiated commercial opportunity rather than merely enlarge the addressable population.

Near term (days), the announcement may support sentiment, but the submitted protocol and company-reported regulator feedback are not trial results. Over 1–3 months, monitor actual trial initiation, site activation and enrollment—not just the stated timeline. The 24-week endpoint plus enrollment and any sample-size expansion make a decisive efficacy readout a longer-dated catalyst; expansion could improve evidentiary power while adding time and capital needs. In 6–18 months, the key read-through is whether peak VO₂, patient-reported function and safety cohere across independently evaluated cohorts.

The competitive implication is most relevant in nonobstructive HCM, where a differentiated approach could matter if efficacy is demonstrated. Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten are relevant obstructive-HCM benchmarks, but cross-trial comparisons would be unreliable. Contrarian point: the market may over-credit procedural alignment as clinical de-risking; conversely, a less monitoring-intensive regimen could have value beyond efficacy if trial data support it. A thesis break would be delayed enrollment, dose-limiting tolerability, or no clinically meaningful pVO₂ benefit. Cash runway, trial costs, full dose-exposure data and current valuation are needed before sizing a directional position.

Key Decisions for Investors

• Do not treat regulator alignment as an efficacy catalyst. Avoid chasing an announcement-driven move; consider only a small, risk-budgeted EWTX event position pending valuation and cash-runway review.
• Set an execution watch for confirmed first-patient dosing, site activation and enrollment cadence. Reassess if initiation slips beyond the company’s stated quarter or if the protocol’s sample-size expansion materially extends the study.
• Track dose escalation, discontinuations, exposure-response and safety alongside pVO₂ and patient-reported outcomes. Weak tolerability or failure to show meaningful functional benefit would invalidate the access-and-differentiation thesis.
• Use Camzyos and aficamten as competitive context, not direct efficacy comps; wait for comparable trial data before expressing a relative-value trade.